| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $676.0M | -5.6% |
| SG&A Expense | $110.0M | -7.6% |
| Operating Income | -$786.0M | +5.9% |
| Pre-tax Income | -$748.0M | +6.0% |
| Income Tax | $0 | — |
| Net Income | -$748.0M | +6.0% |
| EPS (Basic) | -$0.46 | +23.3% |
| EPS (Diluted) | -$0.46 | +23.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $211.0M | -57.9% |
| Current Assets | $1.25B | +3.0% |
| Total Assets | $2.14B | -4.3% |
| Current Liabilities | $105.0M | -5.4% |
| Total Liabilities | $263.0M | +5.2% |
| Stockholders' Equity | $1.88B | -5.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$611.0M | -2.2% |
| Capital Expenditures | $34.0M | +126.7% |
| Investing Cash Flow | -$172.0M | -2250.0% |
| Financing Cash Flow | $492.0M | -40.8% |
| Free Cash Flow | -$645.0M | -5.2% |